Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.

Stefanos BonovasGeorgios K NikolopoulosDaniele PiovaniMarien González-LorenzoKaterina PantavouTheodore LytrasLaurent Peyrin-BirouletSilvio Danese

Published in: British journal of clinical pharmacology (2019)

Budesonide-MMX and mesalamine >2.4 g/day had similar efficacy for induction of clinical and endoscopic remission in active, mild-to-moderate UC; however, mesalamine >2.4 g/day showed better tolerability. Further high-quality research is warranted.

Keyphrases

ulcerative colitis
ultrasound guided
disease activity
rheumatoid arthritis